Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC
Status:
Recruiting
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
The Tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal
saline over 20 minutes after induction of anesthesia and before surgical incision. In the
control group, patients will receive a placebo of 100 mL 0.9% normal saline. The primary
endpoint is reduction in blood loss, while the secondary endpoint was the number of patients
needing transfusion and occurrence of postoperative thrombotic complications (myocardial
infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days
after surgery.